Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_3
2
18%
Ph phase_4
1
9%
Ph phase_2
4
36%
Ph phase_1
4
36%

Phase Distribution

4

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (36.4%)
Phase 24 (36.4%)
Phase 32 (18.2%)
Phase 41 (9.1%)

Trials by Status

completed873%
terminated218%
unknown19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

NCT05957978
completedphase_3

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

NCT03129646
unknownphase_2

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

NCT04906031
completedphase_1

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

NCT00498979
completedphase_1

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

NCT00629200
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05957978Phase 2

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Completed
NCT03129646Phase 3

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Completed
NCT04906031Phase 2

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Unknown
NCT00498979Phase 1

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Completed
NCT00629200Phase 1

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Completed
NCT00311558Phase 1

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Terminated
NCT00255567Phase 3

Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

Completed
NCT01011309Phase 2

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

Completed
NCT01009502Phase 1

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Terminated
NCT01661296Phase 4

Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India

Completed
NCT00996463Phase 2

Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11